Scinai Immunotherapeutics
SCNI
13 hedge funds and large institutions have $623K invested in Scinai Immunotherapeutics in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 9 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0% → 0% (-0%)
24% less funds holding
Funds holding: 17 → 13 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
97% less capital invested
Capital invested by funds: $20.8M → $623K (-$20.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$661K |
| 2 |
Two Sigma Investments
New York
|
+$326K |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$263K |
| 4 |
Morgan Stanley
New York
|
+$146K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$90.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
-$12.6M |
| 2 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
-$2.91M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$701K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$335K |
| 5 |
MA
Mutual Advisors
Omaha,
Nebraska
|
-$280K |
SCNI Hedge Fund Activity: Q4 2020 in Review
13 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2020, worth a combined $623K — down 97% from $20.8M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SCNI and 5 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was State Street, adding an estimated $661K. The largest seller was Ibex Investors, exiting entirely with an estimated $12.6M sold.
- 13 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2020, down from 17 in Q3 2020.
- Funds reported $623K of Scinai Immunotherapeutics stock for Q4 2020, down 97% quarter-over-quarter.
- 5 funds opened new Scinai Immunotherapeutics positions in Q4 2020 and 9 closed out, a net change of -4 holders.
- The largest Scinai Immunotherapeutics buyer in Q4 2020 was State Street, an estimated $661K added.
- The largest Scinai Immunotherapeutics seller in Q4 2020 was Ibex Investors, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2020.